Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gene therapy |
| gptkbp:administeredBy |
specialized treatment centers
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2017-10-18 |
| gptkbp:ATCCode |
L01XL08
|
| gptkbp:blackBoxWarning |
yes
|
| gptkbp:cellTypeUsed |
autologous T cells
|
| gptkbp:cost |
high
|
| gptkbp:developedBy |
gptkb:Kite_Pharma
|
| gptkbp:genericName |
gptkb:axicabtagene_ciloleucel
|
| https://www.w3.org/2000/01/rdf-schema#label |
Yescarta
|
| gptkbp:indication |
gptkb:large_B-cell_lymphoma
gptkb:primary_mediastinal_large_B-cell_lymphoma diffuse large B-cell lymphoma high grade B-cell lymphoma transformed follicular lymphoma |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Gilead_Sciences
|
| gptkbp:mechanismOfAction |
CD19-directed genetically modified autologous T cell immunotherapy
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
cytokine release syndrome
neurological toxicities |
| gptkbp:target |
gptkb:CD19
|
| gptkbp:bfsParent |
gptkb:gene_therapy
|
| gptkbp:bfsLayer |
5
|